## NOTICE OF NEW HAMPSHIRE MEDICAID FEE FOR SERVICE DRUG UTILIZATION REVIEW BOARD PUBLIC HEARING June 30, 2020

The New Hampshire Drug Utilization Review (DUR) Board invites you to attend a public hearing at 2:00 p.m., on June 30, 2020 via Zoom Conference. The DUR meeting will immediately follow this public hearing. The Zoom Conference information will be available 1 week prior to the DUR meeting at

https://www.dhhs.nh.gov/ombp/pharmacy/notices.htm and

https://newhampshire.magellanmedicaid.com/portal/spring/public/nhportalpublic?execution=e1s1.

The purpose of the public hearing is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid Fee for Service pharmacy prior authorization criteria.

The public hearing will begin at 2:00 p.m. and end no later than 3:00 p.m. The DUR meeting will begin at or before 3:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the proposed prior authorization criteria. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the prior authorization criteria.

Written material may also be submitted by the public for DUR Board consideration, if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

If accommodations are needed for communication access such as interpreters, CART (captioning), assistive listening devices, or other auxiliary aids and/or services, please contact Kelly Cote at 603-271-9300 by June 13, 2020. At least 5 business days advance notice is requested in order to assure availability; requests made fewer than 5 days prior to the event will attempt to be accommodated but cannot be guaranteed.

## DRUG UTILIZATION REVIEW BOARD MEETING June 30, 2020 Meeting Agenda

- I. Introductions and Welcome to Board Members
- II. Old Business
  - A. Minutes 10/28/19 review
- III. New Business
  - A. DUR Business Operations
    - Overview of Drug Utilization Patterns for the New Hampshire Medicaid Fee-for Service Program
      - a. Prospective DUR Reports

- b. Utilization Reports
- c. Retrospective DUR Reports
- B. COVID-19 Status Update
- C. Review of DUR Board Bylaws
- D. Review of Current Clinical Prior Authorization Criteria with Proposed Changes
  - Allergen Extract
  - 2. Anti-Fungal Medication for Onychomycosis
  - 3. Anti-Obesity
  - 4. Asthma/Allergy Immunomodulators
  - 5. Atopic Dermatitis
  - 6. Bowel Disorders/GI Motility, Chronic
  - 7. Calcitonin Gene-Related Peptide (CGRP) Inhibitor
  - 8. CNS Stimulant and ADHD/ADD Medications
  - 9. Hepatitis C
  - 10. Long-Acting Opioid Analgesics
  - 11. Pulmonary Arterial Hypertension (Phosphodiesterase Type 5 (PDE-5) Inhibitors)
  - 12. Rho Kinase Inhibitor
  - 13. Short Acting Fentanyl
  - 14. Systemic Immunomodulators
- E. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes
  - 1. Carisoprodol and Combination Medication
  - 2. Direct Renin Inhibitor and Combination
  - 3. Hematopoietic Agent
  - 4. Huntington's Disease
  - 5. Spinraza®
  - 6. Syndros<sup>TM</sup> (dronabinol)
- F. Proposal of New Clinical Prior Authorization Criteria
  - 1. Dupixent®
- G. Proposal of New Preferred Drug List (PDL) Category
  - 1. Anticonvulsants Other
    - a. Rectal
    - b. Nasal

## IV. Adjourn

Further information regarding the agenda items may be obtained after June. 13, 2020. Notice of intent to testify at the public hearing, and/or submittal of written comments, should be directed to Kelly Cote, NH Department of Health and Human Services, 129 Pleasant Street, Concord, NH, 03301, (603) 271-9300, or e-mail at: kelly.cote@dhhs.nh.gov.